摘要
应用计算机检索Pubmed数据库1995-01/2008-01期间和CNKI、维普数据库2001-01/2008-01期间与组织工程心脏瓣膜种子细胞相关的44篇资料显示:临床应用的机械瓣和生物瓣存在一些缺点,而组织工程心脏瓣膜优点包括无需抗凝治疗、抗感染、有活力、具有生长和修复能力,具有很好的前景。组织工程心脏瓣膜种子细胞可来源于:血管、骨髓、血液、脐带、绒毛膜和胚胎干细胞等,这些细胞具有相应特异的细胞表型,并适合产生用作组织工程的细胞外基质。组织工程心脏瓣膜研究已经取得了相当大的进展和令人鼓舞的成绩,但有许多技术问题和临床实际问题尚待解决和克服。要想组织工程心脏瓣膜成功应用于临床,需要更深入的研究:比如可降解多聚物支架材料特性、干细胞分化、尽量发挥自体细胞功能、使用无创技术评价瓣膜生长和重构的速度及质量等,这样就会催生更新进的技术应用于体内安全性实验以及临床前期研究。
Computer-based online research was performed in Pubmed Database from January 1995 to January 2008, China National Knowledge Infrastructure （CNKI） and Vip Database from January 2001 to January 2008, Forty-four publications referred to the seeding cell sources of tissue engineering heart valve demonstrated some disadvantages of clinically used mechanical prosthetic valve and biological valve, Tissue-engineered heart valve had advantages, such as no anticoagulant therapy, infection resistance, cellular viability and the potential to grow and to repair. Seeding cells have different sources, such as blood vessels, bone marrow, blood, umbilical cord, chorionic vesicle and embryonic stem cells, with particular regard to cell phenotypes and their suitability for extracellular matrix production for tissue engineering purposes. Despite an exciting potential for tissue-engineered heart valves, significant technical barriers and clinical problems must be solved and overcome. Further studies should be conducted before widespread clinical application can be envisioned, such as biodegradable polymers, stem cell differentiation, understanding how to harvest the potential of endogenous recruitment of cells and techniques to non-invasively assess the speed and quality of tissue healing and remodeling. This needs to engender a host of novel testing strategies and methods, which will include in vivo safety studies and preclinical studies.
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2008年第29期5719-5722,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
基金
"构建新型复合支架调控组织工程瓣膜力学性能机制研究"国家自然科学基金资助项目(30571839)~~
